Please join us for a Lunch & Learn presentation on the topic of technology licensing, with a focus on technology transfer from educational and other institutions. Josh Smith, an attorney at Tonkon Torp LLP, and Andrew Weinberg, President of AgonOx, Inc, will provide their insights on:
About the Speakers:
Josh Smith and Andrew Weinberg
Josh Smith is a partner at Tonkon Torp and a member of its Entrepreneurial Services, Intellectual Property, Corporate Finance & Transactions, and Mergers & Acquisitions practice groups. His practice is focused on representing and counseling emerging and established companies on a wide variety of intellectual property, corporate, and transactional matters. He counsels clients on venture capital and angel financings, mergers and acquisitions, strategic alliances and joint ventures, technology licensing, commercial agreements, and general business matters – primarily in the technology industry.
Prior to joining Tonkon Torp, Josh was the managing partner of Alto Law Group, a boutique law firm focused on technology and emerging growth companies. He is actively engaged in Oregon’s startup community and a member of the Technology Association of Oregon and Oregon Entrepreneurs Network. Josh graduated magna cum laude from Lewis & Clark Law School.
Andrew Weinberg earned his M.S. and Ph.D. in Biochemistry at Washington State University in 1987. Dr. Weinberg moved to Portland, Oregon in 1990 to work at the VA Medical Center on an autoimmune model for multiple sclerosis (EAE) with Arthur Vandenbark, Ph.D. and Halina Offner, Ph.D. During the course of the autoimmune work Dr. Weinberg discovered that the TNF-receptor, OX40, was expressed on autoAg-specific T cells at the site of autoimmune inflammation and was in part responsible for their pathogenic properties.
Dr. Weinberg moved to the Providence Cancer Center in 1995 as an independent scientist to focus on tumor immunology. There he discovered that OX40 agonists were potent stimulators of tumor immunity in cancer-bearing hosts. In collaboration with Brendan Curti, M.D. and Walter Urba, M.D. at the Providence Cancer Center a human OX40 agonist was tested in a phase I clinical trial.
Thank you to Tonkon Torp for sponsoring this event.